NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Hemophilia A or B

Interventions: Marstacimab

Countries: Japan

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

* Patients who have received at least one dose of this drug after the launch of this drug

Locations (1)

Tokyo, Japan